🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

MICROBIOTA AND BLADDER CANCER

RecruitingNAAges 18 Years - anyMaleCentre Hospitalier Universitaire de Nice
NCT07080333 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In France, bladder cancer (BC) is the fourth leading cause of cancer (14,000 new cases per year). It affects older men (\>60 years old) and smoking is the main identified risk factor (RF). The persistence of a high sex ratio despite the increase in smoking among women has led to research into other environmental RFs for BC, which may include the microbiota. Recently, the concept of urinary microbiota in asymptomatic patients has been accepted. Studies on the urinary microbiota have shown dysbiosis associated with certain urogenital pathologies. Thus, similar to certain dysbiosis of the colonic mucosa microbiota associated with CRC, it is possible that certain bacteria or viruses in the bladder tissue microbiota may be involved in bladder carcinogenesis. An epidemiological study conducted by our laboratory showed a prevalence of BC of 14% (7/50) in patients carrying the bacterium Actinot

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age \> 18 years old * Male * First RTUV for suspected CV in the presence of macroscopic haematuria or other clinical signs and/or urinary cytology and/or cystoscopy and/or imaging tests suggestive of CV * Signed informed consent form * Affiliation with a social security scheme Exclusion Criteria: * Antibiotic use within 3 months prior to inclusion * Current urinary tract infection (urine culture recommended by the AFU prior to RTUV) * History of surgical treatment of the urinary and genital tracts within the last 6 months prior to inclusion * History of RTUV * History of pelvic radiotherapy * Interstitial cystitis * Patients with an indwelling urinary catheter * Vulnerable patients: minors, patients under guardianship or curatorship * Patients with benign tumours after receipt of the pathological report (inverted papilloma, non-tumour inflammatory lesion)
💊

What it tests

  • biopsy
📍

Where

8 sites
Cannes Hospital
Cannes, France
Marseille university Hospital
Marseille, France
Menton Hospital
Menton, France
Nice University Hospital
Nice, France
Nimes University hospital
Nîmes, France
Paris University Hospital
Paris, France
Rennes University Hospital
Rennes, France
Tours University Hospital
Tours, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy